Globe on Big Pharma R&D Failure
3 Comments
Law Bytes
Episode 77: The Complexity of Internet Content Regulation – A Conversation with CIPPIC's Vivek Krishnamurthy
February 1, 2021
Search Results placeholder
Recent Posts
The Law Bytes Podcast, Episode 77: The Complexity of Internet Content Regulation – A Conversation with CIPPIC’s Vivek Krishnamurthy 
Beware the Unintended Consequences: Some Warning Signs for Canada from the Australian Government Battle With Facebook 
The Copyright Bill That Does Nothing: Senate Bill Proposes Copyright Reform to Support Media Organizations 
Circumventing Parliament: How Bill C-10 Dramatically Reduces Parliamentary Oversight and Review Over Broadcast Policy 
Afraid to Lead: Canadian Government Launches Timid Consultation on Implementing Copyright Term Extension
So, repeal C-22
If the drug companies can renege, then so can the goodies that were given to them be taken away.
Seems pretty straightforward to me.
Why aren’t there such things as charitable venture capital orgs? After-all many charities (eg JDRC) contribute to for-profit orgs. It seems to me that charitable donations would go much further if the beneficiaries of donations (R&D orgs) had to contribute returns back to charities. The role of charities like JDRC then would be to encourage R&D firms to take greater risks.
Hey, Michael! Don’t be so ungrateful or narrow minded. What about the bevy of busy lawyers who make gazillions every year doing “research” on their endless litany of pharmaceutical patent cases in the courts? What about all that useful literature and education directed at the medical profession, so that they are better informed about what pills their patients should pop? That takes a lot of “research and development”. And what about all the consumer focus group “research†that goes into those cute Cialis TV commercials?